)
MOHCCN Seminar Series
This seminar series features virtual talks from MOHCCN research partner investigators and trainees, providing a platform for MOHCCN members to share their ongoing work in precision oncology with the wider Network. These seminars will be of interest primarily to cancer researchers, clinicians, trainees, and members of the MOHCCN Patient Working Group across the country.
Upcoming seminars
Next: Friday, December 6th 2024 - Pan-Canadian projects
12 pm PT / 1pm MT / 2pm CT / 3pm ET / 4pm AT / 4:30pm NT
REGISTER NOW!
Agenda
Pan-Canadian projects overview
Dr. Véronique LeBlanc - Network Program Manager and Scientific Writer, TFRI
CAN-PREDICT-IT and CAN-PIVOT projects
CCTG PM.2: Canadian initiative to measure, predict and assess cancer treatment outcomes in patients treated with immune-oncotherapeutics (CAN-IMPACT-IO)
Dr. Philippe Bedard - Medical Oncologist, Princess Margaret Cancer Centre; Associate Professor of Medicine, University of Toronto; MOHCCN project lead
Dr. Anna Spreafico - Medical Oncologist, Princess Margaret Cancer Centre; Associate Professor of Medicine, University of Toronto; MOHCCN project lead
Enabling precision oncology in rare types of gynecologic cancer project
The long and winding road to better outcomes in rare gynecological cancers: Striding towards Terry Fox's vision
Dr. Mark Carey - Gynecologic Oncologist, Vancouver Coastal Health; Clinical professor, Division of Gynecologic Oncology, University of British Columbia; MOHCCN project lead
Identifying markers of immunotherapy response in ovarian clear cell carcinoma
Dr. Melica Brodeur - Gynecologic oncologist, Jewish general Hospital; Principal investigator, Lady David Institute for Medical Research; Assistant Professor, Department of Obstetrics & Gynecology and Department of Oncology, McGill University
Diagnostic accuracy of pre-operative circulating tumour DNA in mucinous ovarian cancers
Dr. Elizabeth Tremblay - Gynecologic oncologist, Centre hospitalier de l'Université de Montréal (CHUM); Clinical investigator, Centre de recherche du CHUM (CR-CHUM)
This event will be co-chaired by Dr. Denis Petitclerc, a member of the MOHCCN Patient Working Group, and Dr. Véronique LeBlanc, Program Manager and Scientific Writer, MOHCCN.
The MOHCCN seminars will resume in 2025 - stay tuned for more details!
Previous seminars
2024
Atlantic Cancer Consortium (ACC)
Thursday, October 24 2024
PR2C consortium activities update
Dr. Sherri Christian - Professor, Department of Biochemistry, Memorial University of Newfoundland; MOHCCN consortium lead (PR2C)
Biobank update
Biobank NL overview
Daniel Loos - Coordinator, Biobank NL
Research presentations
THSD4: a novel mediator of immune exclusion and pembrolizumab response in breast cancer
Olivia Walker - PhD candidate, Marcato lab, Department of Pathology, Faculty of Medicine, Dalhousie University
This event was co-chaired by Christine Wu, a member of the MOHCCN Patient Working Group, and Véronique LeBlanc, PhD, Program Manager and Scientific Writer, MOHCCN.
Prairie Cancer Consortium (PR2C)
Thursday, September 26 2024
PR2C consortium activities update
Dr. Jennifer Chan - Associate Professor, Cumming School of Medicine, Department of Pathology and Laboratory Medicine, University of Calgary; Director, Arnie Charbonneau Cancer Institute; MOHCCN consortium lead (PR2C)
Research presentations
Precision Choice at the Point of Care
Dr. Laura Hopkins - Professor, Department of Oncology, College of Medicine, University of Saskatchewan; Gynecologic oncologist, Saskatchewan Cancer Agency; MOHCCN cohort lead
Predicting response to immune checkpoint blockades in sarcoma
Dr. Hyojin Song - Postdoctoral associate, Morrissy lab, Cumming School of Medicine, University of Calgary
This event was co-chaired by Debbie Duclos, a Registered Nurse and member of the MOHCCN Patient Working Group from Campbellville, ON, and Véronique LeBlanc, PhD, Program Manager and Scientific Writer, MOHCCN.
BC Cancer Consortium (BC2C)
Thursday, June 27 2024
BC2C CONSORTIUM ACTIVITIES UPDATE
Dr. Daniel Renouf - Medical Oncologist and Executive Medical Director, BC Cancer - Vancouver; Associate Professor, Faculty of Medicine, UBC; MOHCCN consortium lead (BC2C)
RESEARCH PRESENTATIONS
Multimode whole genome approaches to plasma-based disease monitoring in triple-negative breast cancer
Dr. Samuel Aparicio - Professor, Department of Pathology and Laboratory Medicine, UBC; Head, Department of Breast and Molecular Oncology, BC Cancer Research Institute; MOHCCN cohort lead
Synovial sarcoma chromatin dynamics reveal a continuum in SS18::SSX reprogramming
Kiera Lee - MD/PhD Candidate, Department of Microbiology and Immunology, Michael Smith Laboratories, UBC
This event was co-chaired by Rosilene Kraft, PhD, PEng, MOHCCN Patient Working Group member, and Véronique LeBlanc, PhD, Program Manager and Scientific Writer, MOHCCN.
Marathon of Hope - Québec (MOH-Q)
Thursday, April 25 2024
MOH-Q CONSORTIUM ACTIVITIES UPDATE
Anne-Marie Mes-Masson, PhD, FRSC, FCAHS - Professor, Department of Medicine, Université de Montréal; Associate Scientific Director, Basic and Translational Research, Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM); MOHCCN consortium lead (MOH-Q)
Morag Park, CQ, PhD, FRSC, FCAHS - Distinguished James McGill Professor, Departments of Oncology, Biochemistry, and Medicine, McGill University; Diane and Sal Guerrera Chair in Cancer Genetics; Director, Rosalind and Morris Goodman Cancer Institute, McGill University; MOHCCN consortium lead (MOH-Q)
RESEARCH PRESENTATIONS
Role of gut and intratumoral microbiota on response to immune checkpoint inhibitors in lung cancer and melanoma
Arielle Elkrief, MD, FRCPC - Assistant Professor, Department of Hematology-Oncology, Université de Montréal; Medical Director, CHUM Microbiome Centre; MOHCCN cohort lead
View abstract and plain language summary
Using unsupervised clustering of multiomic data to define molecular and transcriptional subtypes of rare pancreatic neuroendocrine tumours
Joan Miguel Romero, MSc - MD-PhD Candidate, Division of Experimental Medicine, Rosalind and Morris Goodman Cancer Institute and Research Institute of the McGill University Health Centre (RI-MUHC), McGill University
View abstract and plain language summary
This event was co-chaired by Natalie A-K, BSc, MBA, CPA-CMA, de novo stage 4 breast cancer patient, MOHCCN Patient Working Group and Network Council member, and Véronique LeBlanc, PhD, Program Manager and Scientific Writer, MOHCCN.
Princess Margaret Cancer Consortium (PM2C)
Thursday, February 29 2024
PM2C CONSORTIUM ACTIVITIES UPDATE
Dr. Lillian Siu - Medical Oncologist, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN); MOHCCN consortium lead (PM2C)
Dr. Amber Simpson - Associate Professor, Queen's University; Canada Research Chair in Biomedical Computing and Informatics; MOHCCN Kingston / Queen's University institutional lead
RESEARCH PRESENTATIONS
Identification and clinical implications of circular RNA in cancer
Dr. Hansen He - Senior Scientist, PMCC, UHN; Professor, Department of Medical Biophysics, University of Toronto; MOHCCN cohort lead
View abstract and plain language summary
Shedding light on the surge: Investigating the etiology of young onset colorectal cancer
Dr. Kevin Wang - Medical Oncology Fellow, Eliot Phillipson Clinician-Scientist Training Program, PMCC, UHN
View abstract and plain language summary
2022
MOHCCN Seminar Series: Atlantic Cancer Consortium
Monday, June 6 2022
Presenters
- “Transforming the data ecosystem for precision oncology research and care” Dr. Robin Urquhart, PhD. Associate Professor, Department of Community Health and Epidemiology, Dalhousie University Nova Scotia Lead/PI for the Atlantic Cancer Consortium
- “Clinical and social patient outcomes and their predictors” Dr. Sevtap Savas, PhD. Professor, Division of Biomedical Sciences, Faculty of Medicine, Memorial University
- “Small RNA in extracellular vesicles (EVs) of GBM, grade 4 astrocytoma recurrence” Dr. Jeremy Roy, PhD. Scientist, Atlantic Cancer Research Institute. Adjunct (Scholar) Professor, Department of Medical Neuroscience, Dalhousie University Associate Member, Beatrice Hunter Cancer Research Institute and Dr. Adrienne Weeks, MD PhD. Assistant Professor, Division of Neurosurgery, Faculty of Medicine, Dalhousie University Atlantic Canada Research Institute and Dalhousie University
- “Applying omics and bioinformatics to investigate novel mediators of breast cancer progression” Marie-Claire Wasson. PhD Candidate, Department of Pathology, Faculty of Medicine, Dalhousie University Trainee, Cancer Research Training Program, Beatrice Hunter Cancer Research Institute
MOHCCN Seminar Series: Marathon of Hope - Québec
Monday, February 7 2022
Presenters
- Natasha Szuber, MD M.Sc. FRCPC “Advances in myeloproliferative neoplasms”
- Sonia del Rincón, PhD “Targeting MNK1/2 in cancer: What have we learned and where are we going?”
- Yacine Bareche, PhD “Leveraging big data of immune checkpoint blockade response identifies novel potential targets”
- Ian Watson, PhD “The spatial immune landscape of melanoma”
2021
MOHCCN Seminar Series: Precision Medicine Initiatives at the Princess Margaret Cancer Centre Consortium
Presenters
- Dr. Lillian Siu
- Dr. Phillippe Bedard
- Dr. Alberto Hernando Calvo
MOHCCN Seminar Series: TFRI's EPPIC Program
Keynote
- Dr. Daniel Renouf, MD, MPH, FRCPC, presenting Precision Medicine in Pancreatic Cancer: The TFRI EPPIC Program
Presenters
- Dr. Yifan Wang, MD, PhD (candidate), presenting Informing pancreatic cancer care through ambulatory oncology clinic-based germline testing models and precision medicine
- James Topham (BC Genome Sciences Centre) and Erica Tsang (BC Cancer) presenting KRAS WT Pancreatic Cancer
Moderator
- Dr. George Zogopoulos, MD, PhD, FRCS(C), FACS. Associate Professor of Surgery and Oncology, McGill University and Scientist, Research Institute of the McGill University Health Centre and Rosalind and Morris Goodman Cancer Institute